Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Day, Ian NM
Gu, Dongfeng
Ganderton, Rosalind H
Spanakis, Emmanuel
and
Ye, Shu
2001.
Epidemiology and the genetic basis of disease.
International Journal of Epidemiology,
Vol. 30,
Issue. 4,
p.
661.
Paschke, Thilo
Riefler, Michelle
Schuler-Metz, Annette
Wolz, Lucie
Scherer, Gerhard
McBride, Colleen M
and
Bepler, Gerold
2001.
Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method.
Toxicology,
Vol. 168,
Issue. 3,
p.
259.
Nakajima, Miki
Kuroiwa, Yukio
and
Yokoi, Tsuyoshi
2002.
INTERINDIVIDUAL DIFFERENCES IN NICOTINE METABOLISM AND GENETIC POLYMORPHISMS OF HUMAN CYP2A6.
Drug Metabolism Reviews,
Vol. 34,
Issue. 4,
p.
865.
Xu, Chun
Goodz, Shari
Sellers, Edward M.
and
Tyndale, Rachel F.
2002.
CYP2A6 genetic variation and potential consequences.
Advanced Drug Delivery Reviews,
Vol. 54,
Issue. 10,
p.
1245.
Tyndale, Rachel F.
and
Sellers, Edward M.
2002.
Genetic Variation in CYP2A6-Mediated Nicotine Metabolism Alters Smoking Behavior.
Therapeutic Drug Monitoring,
Vol. 24,
Issue. 1,
p.
163.
Lerman, Caryn
Shields, Peter G
Wileyto, E Paul
Audrain, Janet
Pinto, Angela
Hawk, Larry
Krishnan, Shiva
Niaura, Ray
and
Epstein, Leonard
2002.
Pharmacogenetic investigation of smoking cessation treatment.
Pharmacogenetics,
Vol. 12,
Issue. 8,
p.
627.
Peet, Norton P
2002.
The utility of predictivity in drug discovery and use.
Drug Discovery Today,
Vol. 7,
Issue. 4,
p.
228.
Sellers, Edward M.
Tyndale, Rachel F.
and
Fernandes, Leona C.
2003.
Decreasing smoking behaviour and risk through CYP2A6 inhibition.
Drug Discovery Today,
Vol. 8,
Issue. 11,
p.
487.
Howard, Lisa A
Ahluwalia, Jasjit S
Lin, Shih-Ku
Sellers, Edward M
and
Tyndale, Rachel F
2003.
CYP2E1*1D regulatory polymorphism.
Pharmacogenetics,
Vol. 13,
Issue. 6,
p.
321.
Tricker, Anthony R
2003.
Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour.
Toxicology,
Vol. 183,
Issue. 1-3,
p.
151.
Lerman, C
Wileyto, E P
Patterson, F
Rukstalis, M
Audrain-McGovern, J
Restine, S
Shields, P G
Kaufmann, V
Redden, D
Benowitz, N
and
Berrettini, W H
2004.
The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial.
The Pharmacogenomics Journal,
Vol. 4,
Issue. 3,
p.
184.
Sampablo Lauro, I.
and
Angrill Paxeras, J.
2004.
Actualización en el tratamiento del tabaquismo.
Archivos de Bronconeumología,
Vol. 40,
Issue. 3,
p.
123.
O’Loughlin, J
Paradis, G
Kim, W
DiFranza, J
Meshefedjian, G
McMillan-Davey, E
Wong, S
Hanley, J
and
Tyndale, R F
2004.
Genetically decreasedCYP2A6and the risk of tobacco dependence: a prospective study of novice smokers.
Tobacco Control,
Vol. 13,
Issue. 4,
p.
422.
Schoedel, Kerri A
Hoffmann, Ewa B
Rao, Yushu
Sellers, Edward M
and
Tyndale, Rachel F
2004.
Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.
Pharmacogenetics,
Vol. 14,
Issue. 9,
p.
615.
Sampablo Lauro, I.
and
Angrill Paxeras, J.
2004.
Update on the Treatment of Smoking Dependence.
Archivos de Bronconeumología ((English Edition)),
Vol. 40,
Issue. 3,
p.
123.
Huang, Shuwen
Cook, Derek G.
Hinks, Lesley J.
Chen, Xiao-he
Ye, Shu
Gilg, Julie A.
Jarvis, Martin J.
Whincup, Peter H.
and
Day, Ian N.M.
2005.
CYP2A6, MAOA, DBH, DRD4, and 5HT2A genotypes, smoking behaviour and cotinine levels in 1518 UK adolescents.
Pharmacogenetics and Genomics,
Vol. 15,
Issue. 12,
p.
839.
Walsh, Margaret M.
and
Ellison, James A.
2005.
Treatment of Tobacco Use and Dependence: The Role of the Dental Professional.
Journal of Dental Education,
Vol. 69,
Issue. 5,
p.
521.
Spitz, Margaret R.
Wu, Xifeng
and
Mills, Gordon
2005.
Integrative Epidemiology: From Risk Assessment to Outcome Prediction.
Journal of Clinical Oncology,
Vol. 23,
Issue. 2,
p.
267.
Vasconcelos, G M
Struchiner, C J
and
Suarez-Kurtz, G
2005.
CYP2A6 genetic polymorphisms and correlation with smoking status in Brazilians.
The Pharmacogenomics Journal,
Vol. 5,
Issue. 1,
p.
42.
Gambier, N
Batt, A-M
Marie, B
Pfister, M
Siest, G
and
Visvikis-Siest, S
2005.
Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort.
The Pharmacogenomics Journal,
Vol. 5,
Issue. 4,
p.
271.